Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

For some individuals, obesity may play a secondary role in their medical problems by exacerbating existing conditions. For ...

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...

In the first randomized controlled trial in patients with vestibular migraine, galcanezumab outperformed placebo in reducing ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...